A commercial vaccine for ovine toxoplasmosis
- 1 March 1995
- journal article
- review article
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 110 (S1) , S11-S16
- https://doi.org/10.1017/s003118200000144x
Abstract
This paper describes the development of the first commercial vaccine for toxoplasmosis. The vaccine comprises live tachyzoites of the S48 'incomplete' strain of Toxoplasma gondii and is deployed to control toxoplasma abortion in sheep. A discussion of protective immune mechanisms and recent studies on host responses to the vaccine is also included.Keywords
This publication has 45 references indexed in Scilit:
- Experimental challenge of sheep 18 months after vaccination with a live (S48) Toxoplasma gondii vaccineVeterinary Record, 1993
- Treatment of ovine toxoplasmosis with a combination of sulphamezathine and pyrimethamineVeterinary Record, 1993
- Vaccination of sheep with a live incomplete strain (S48) of Toxoplasma gondii and their immunity to challenge when pregnantPublished by Wiley ,1991
- Immune response after immunization with an experimental Toxoplasma gondii ISCOM vaccineVaccine, 1991
- Further studies in the use of monensin in the control of experimental ovine toxoplasmosisJournal of Comparative Pathology, 1988
- Monensin and the control of experimental ovine toxoplasmosis: a systemic effectPublished by Wiley ,1987
- Interferon-γ suppresses the growth of Toxoplasma gondii in human fibroblasts through starvation for tryptophanMolecular and Biochemical Parasitology, 1986
- Experimental infection of pregnant sheep with Toxoplasma gondii: Pathological and immunological observations on the placenta and foetusJournal of Comparative Pathology, 1986
- Immunosuppression in toxoplasmosis: Studies in lambs and sheep infected with louping-ill virusJournal of Comparative Pathology, 1982
- Identification of the Activator System for Antibody to Toxoplasma as the Classical Complement PathwayThe Journal of Infectious Diseases, 1980